NDA 020796 · Orion Pharma
Comtan
Entacapone · Oral · Catechol-O-Methyltransferase Inhibitor
NovelLast checked: Nov 19, 2026Latest source record: Feb 22, 2016 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1999
Oct 19, 1999
Approved uses
1
Original approval plus efficacy supplements
Registered trials
71
14 Phase 3, 5 recruiting
FAERS reports
4,252
3,020 serious, 653 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 30, 2023.
INDICATIONS Entacapone tablets are indicated as an adjunct to levodopa and carbidopa to treat end-of-dose “wearing-off” in patients with Parkinson’s disease (see CLINICAL PHARMACOLOGY, Clinical Studies). Entacapone tablet’s effectiveness has not been systematically evaluated in patients with Parkinson’s disease who do not experience end-of-dose “wearing-off”.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- COMTAN · ENTACAPONE 200MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Entacapone" as an intervention, any sponsor and status, largest first.
- Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa TherapyPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT00099268 · 747 participants · Start Sep 2004 · Primary completion Nov 2008
Drug: Carbidopa/levodopa/entacapone; Immediate release carbidopa/levodopa · For: Parkinson's Disease
Sites: Birmingham, Alabama; Scottsdale, Arizona; La Jolla, California · 73 sites in all
- Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor FluctuationsPivotal-lookingTerminated
Eisai LimitedEisai
NCT00360308 · 723 participants · Start Nov 2006 · Primary completion Apr 2008
Drug: Placebo; E2007 and 1 more · For: Parkinson's Disease
Sites: Toulouse, France
- Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With "Wearing-off" PhenomenonPivotal-lookingCompleted
Bial - Portela C S.A.Industry
NCT01568073 · 600 participants · Start Mar 2011 · Primary completion Nov 2013
Drug: BIA 9-1067; Entacapone and 4 more · For: Parkinson's Disease
Sites: S. Mamede Do Coronado, Portugal
- Evaluation of 611 in Chinese Adults Patients With Moderate to Severe Chronic Obstructive Pulmonary DiseasePivotal-lookingRecruiting
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.Industry
NCT07039669 · 594 participants (planned) · Start Jul 16, 2025 · Primary completion Sep 2028
Drug: 611; Placebo · For: Pulmonary Disease, Chronic Obstructive (COPD)
Sites: Beijing, China; Shenzhen, China; Nanjing, China · 4 sites in all
- Evaluation of 611(Recombinant Humanized Anti-interleukin-4 Receptor Alpha IgG4 Monoclonal Antibody) in Chinese Adults With Moderate to Severe Atopic DermatitisPivotal-lookingCompleted
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.Industry
NCT06173284 · 519 participants · Start Jan 22, 2024 · Primary completion Sep 26, 2025
Drug: 611; Matching placebo · For: Dermatitis, Atopic
Sites: Beijing, China; Nanchang, China; Hangzhou, China · 4 sites in all
- A Study to Evaluate Fixed Dose Carbidopa/Levodopa/Entacapone Versus Immediate Release Carbidopa/LevodopaPivotal-lookingCompleted
NovartisNovartis (NVS)
NCT00134966 · 493 participants · Start Aug 2005 · Primary completion Sep 2007
Drug: capsules containing: carbidopa (25 mg), levodopa (100 mg), entacapone (200 mg) · For: Parkinson's Disease
Sites: Phoenix, Arizona; La Jolla, California; Reseda, California · 60 sites in all
- Evaluation of 611 in Combination With Topical Corticosteroid in Participants With Moderate to Severe Atopic DermatitisPivotal-lookingCompleted
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.Industry
NCT06554847 · 417 participants · Start Sep 23, 2024 · Primary completion Oct 20, 2025
Drug: 611; Placebo and 1 more · For: Dermatitis, Atopic; Eczema, Atopic
Sites: Shanghai, China; Hangzhou, China; Ningbo, China
- A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's DiseasePivotal-lookingCompleted
Kyowa Kirin Co., Ltd.Industry
NCT00199394 · 405 participants · Start Nov 2004 · Primary completion Oct 2005
Drug: Istradefylline (KW-6002) · For: Parkinson's Disease
Sites: Slough, United Kingdom
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- hallucination509
- fall493
- dyskinesia491
- drug ineffective356
- death353
- parkinson^s disease289
- confusional state279
- gait disturbance273
- tremor273
- on and off phenomenon259
- somnolence208
- fatigue207
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 22 |
| 2005 | 18 |
| 2006 | 20 |
| 2007 | 31 |
| 2008 | 58 |
| 2009 | 36 |
| 2010 | 79 |
| 2011 | 68 |
| 2012 | 57 |
| 2013 | 55 |
| 2014 | 81 |
| 2015 | 105 |
| 2016 | 141 |
| 2017 | 333 |
| 2018 | 333 |
| 2019 | 375 |
| 2020 | 390 |
| 2021 | 409 |
| 2022 | 391 |
| 2023 | 277 |
| 2024 | 317 |
| 2025 | 378 |
| 2026 | 277 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
Sponsor: Orion Pharma
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.